MML Investors Services LLC Raises Holdings in Zoetis Inc. (NYSE:ZTS)

MML Investors Services LLC boosted its position in shares of Zoetis Inc. (NYSE:ZTS) by 3.2% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 72,982 shares of the company’s stock after acquiring an additional 2,276 shares during the period. MML Investors Services LLC’s holdings in Zoetis were worth $14,259,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Darwin Wealth Management LLC acquired a new stake in shares of Zoetis during the third quarter worth about $31,000. First Personal Financial Services purchased a new position in Zoetis during the third quarter worth about $33,000. Capital Performance Advisors LLP purchased a new stake in Zoetis in the 3rd quarter valued at approximately $33,000. Dunhill Financial LLC raised its stake in shares of Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after buying an additional 75 shares in the last quarter. Finally, Quarry LP raised its position in Zoetis by 273.2% in the second quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after acquiring an additional 153 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have recently commented on ZTS. JPMorgan Chase & Co. boosted their price target on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Piper Sandler raised their target price on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. Stifel Nicolaus upped their price target on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Wednesday, September 18th. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, UBS Group assumed coverage on Zoetis in a report on Monday. They set a “neutral” rating and a $196.00 target price on the stock. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $216.70.

Zoetis Stock Down 0.8 %

Shares of Zoetis stock opened at $176.71 on Wednesday. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $201.92. The firm has a market capitalization of $79.73 billion, a PE ratio of 33.22, a price-to-earnings-growth ratio of 2.88 and a beta of 0.89. The stock’s fifty day moving average is $181.72 and its 200-day moving average is $181.12.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. During the same period in the previous year, the firm earned $1.36 earnings per share. Zoetis’s quarterly revenue was up 11.6% on a year-over-year basis. Equities analysts anticipate that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st were issued a dividend of $0.432 per share. The ex-dividend date of this dividend was Thursday, October 31st. This represents a $1.73 annualized dividend and a dividend yield of 0.98%. Zoetis’s dividend payout ratio is 32.52%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.